Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma

Yan Li 1,2†, Young K Hong 1,3†, Xingtong Wang 1,4, Harshul Pandit 1,2, Qianqian Zheng 1,5 †, Youxi Yu 1,4, Xiaoju Shi 1,4, Yujia Chen 1,4, Min Tan 1, Zachary Pulliam 1, Neal Bhutiani 1, Andrew Lin 3, Jeremy Badach 3, Ping Zhang 3 & Robert CG Martin 1,2

1Division of Surgical Oncology, Hiram C. Polk Jr., M.D. Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA
2Department of Pharmacology & Toxicology, University of Louisville School of Medicine, Louisville, KY, USA
3Division of Surgical Oncology, Department of Surgery, Cooper University Hospital, Camden, NJ, USA
4The First Hospital of Jilin University, Jilin University, Changchun, China
5Basic Medicine College, China Medical University, Shenyang, China

Correspondence
RCG Martin, Division of Surgical Oncology, Upper Gastrointestinal and Hepato-Pancreatico-Biliary Clinic, 315 E Broadway - #311, Louisville, KY 40202, USA.
E-mail: robert.martin@louisville.edu

†Equal contributors.

Received 17 March 2022;
Revised 19 July and 21 October 2022;
Accepted 27 October 2022
doi: 10.1002/cti2.1430

Abstract

Objectives. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a poor prognosis. PDAC has poor response to immunotherapy because of its unique tumour microenvironment (TME). In an attempt to stimulate immunologically silent pancreatic cancer, we investigated the role of epigenetic therapy in modulating the TME to improve immunogenicity.

Methods. In vitro human PDAC cell lines MiaPaca2 and S2-013 were treated with 5μM 3-Deazaneplanocin A (DZNep, an EZH2 inhibitor) and 5 μM 5-Azacytidine (5-AZA, a DNMT1 inhibitor). In vivo orthotopic murine tumour models using both murine PAN02 cells and KPC cells inoculated in immunocompetent C56/BL7 mice were treated with anti-PD-L1 combined with DZNep and 5-AZA. Short hairpin knockdown (KD) of EZH2 and DNMT1 in PAN02 cells for the orthotopic murine tumour model was established to validate the drug treatment (DZNep and 5-AZA). qRT-PCR and microarray assays were performed for the evaluation of Th1-attracting chemokines and cancer-associated antigen induction.

Results. Drug treatments induced significant upregulation of gene expressions of Th1-attracting chemokines, CXCL9 and CXCL10, and the cancer–testis antigens, NY-ESO-1, LAGE and SSX-4 (P < 0.05). In orthotopic tumour models, inoculation of PAN02 cells or KPC cells demonstrated significant tumour regression with corresponding increased apoptosis and infiltration of cytotoxic T lymphocytes in the combination treatment group. In the orthotopic Pan02-KD model, the anti-PD-L1 treatment also caused significant tumour regression.

Conclusion. We demonstrate that immunotherapy for PDAC can be potentiated with epigenetic therapy by increasing cancer-associated antigen expression and increased T-cell trafficking across the immunosuppressive tumour
INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis despite advances in multimodality therapy. While there has been an improvement in overall survival with systemic chemotherapy using a combination regimen of FOLFIRINOX or Gemcitabine–Abraxane, there remains a great need for more durable and yet tolerable treatment strategies. Immunotherapy has demonstrated impressive efficacy with complete durable responses in melanoma and non-small-cell lung cancer, which raises the question of whether immunotherapy can be applicable for PDAC. However, despite initial high expectations, immunotherapy for pancreatic cancer has been met with dismal response rates. Dense stromal tissue associated with PDAC contributes to this low response rate. A fibrotic immunosuppressive tumour microenvironment may ultimately inhibit cytotoxic T-cell infiltration into the tumour. Because the higher prevalence of tumour-infiltrating lymphocytes has been associated with improved overall survival and tumour response, strategies to increase T-cell infiltration are critical to immunotherapy’s success.

Recently, epigenetic aberrations have been elucidated in the immunosuppressive tumour microenvironment by inhibiting chemokines responsible for T-cell infiltration. In cancer cells, aberrant hypermethylation of CpG islands in DNA promoter regions and histone tail modifications often cause silencing of critical genes without a gene mutation present compared with healthy cells. As it is known, normal epigenetic modulation is regulated at the histone tail by Polycomb Repressor Complex 2 (PRC2). However, there is an aberrant activity of PRC2 in cancer cells because of the aberrant overexpression of catalyst subunit Enhancer of Zeste Homolog 2 (EZH2). At the gene promoter level, overexpression of DNA Methyltransferase 1 (DNMT1) is the driving protein that aberrantly methylates CpG island DNA promoter regions of various genes to silence them. Recent analyses of pancreatic cancer by molecular subtyping have elucidated morphologically similar pancreatic cancer into several subtypes, predominantly classical, quasimesenchymal, squamous and basal-like, with variable prognoses of overall survival. The transcriptional subtypes are determined by the level of epigenetic dysregulation and silencing of key genetic loci promoting classical pancreatic tumours with better survival outcome. As a result, there has been an attempt to target epigenetic dysregulation in pancreatic cancer with epigenetic therapy. In particular, accumulating evidence indicates that the migration of T lymphocytes into the tumour microenvironment can be suppressed by epigenetic silencing of attracting chemokines genes such as CXCL 9 and CXCL10. These attracting chemokines further control and modulate immune helper and effector T-lymphocyte trafficking. In contrast, higher infiltration of tumour-infiltrating lymphocytes in the tumour microenvironment is observed with upregulation of associated chemokine expressions responsible for T-cell trafficking into the tumour cell niche.

Regarding the efficacy of immunotherapy, it is critical for immune cells to recognise the neoantigen targets on cancer cells. In fact, immunogenicity is most often correlated to the level of somatic mutation rate, that is, the highest response rates of immunotherapy in melanoma and non-small-cell adenocarcinoma are connected to high somatic mutation rates from ultraviolet light and cigarette smoke, respectively. Although there are somatic mutations associated with smoke exposure in PDAC, most of the gastrointestinal cancers, including pancreatic cancer, are associated with low somatic mutation rates and often considered immunologically silent. While mutated neoantigens may be limited in pancreatic cancer, cancer–testis antigens (CTAs) can serve as potential neoantigen targets because they are expressed aberrantly in cancer cells. CTAs are expressed in testis and placenta but are protected from the immune system because they lack multiple histocompatibility complex (MHC)
expression on their cell surfaces. However, the problem is that aberrant hypermethylation at the CpG promoter regions causes minimal levels of expression in most gastrointestinal tumours, allowing evasion of the immune response as a result.

Therefore, we aimed to investigate whether targeting aberrant epigenetic markers with epigenetic therapy in combination with immunotherapy can augment the effect of immunotherapy in PDAC by upregulation of cancer-associated antigen expression, increasing T-cell migration into the tumour microenvironment and ultimately causing tumour regression.

RESULTS

Increased PD-L1 expression in PDAC compared with normal parenchyma

To compare the immunosuppressive tumour microenvironment in PDAC to its surrounding native pancreatic tissue, we surveyed the National Cancer BioInformatics Affymetrix GEO database (https://www.ncbi.nlm.nih.gov/geoprofiles/88170422). For our dataset, a total of 45 patients’ PDAC tumour samples were evaluated using a microarray gene expression kit with multiple gene outputs. This dataset was surveyed for the relative gene expression levels of PD-L1 in PDAC compared with adjacent healthy pancreatic tissue. The patients’ PDAC samples were initially analysed for genes expressed in PDAC cells compared with its own adjacent healthy pancreas parenchyma. We wanted to determine whether there was any difference in PD-L1 expression on the tumour surface compared with the surrounding normal pancreatic parenchyma level. There was a statistically significant increase in PD-L1 expression in the tumour tissue compared with adjacent normal pancreatic tissue (Supplementary figure 1; P < 0.01). These elevated levels of PD-L1 expression suggest that PDAC has a predominantly immunosuppressive tumour microenvironment, contributing to a poorly immunogenic histology for immunotherapy.

Upregulation of chemokines CXCL9 and CXCL10

Chemokines CXCL9 and CXCL10 are known to be aberrantly methylated and play a critical role in immune trafficking across tumour microenvironments. Given the epigenetically repressed CXCL9 and CXCL10 as a known barrier for immunotherapy, we demonstrated an upregulation of chemokines CXCL9 and CXCL10 in two human pancreatic adenocarcinoma cell lines, MiaPaca2 and S20-13, by treatment of combination of 5 μM DZNep and 5 μM 5-AZA with 10 ng mL⁻¹ IFN-γ. CXCL9 and CXCL10 were minimally expressed in the control group when treated with IFN-γ alone and achieved moderate gene expression when cells were treated with either DZNep or 5-AZA alone. However, the addition of both epigenetic drugs combined provided a significant upregulation of both CXCL9 (relative gene fold 2.3 x 10³ ± 54) and CXCL10 (relative gene fold 1.0 x 10⁵ ± 6.7 x 10³; Figure 1). The combination of inhibiting EZH2 and inhibiting DNMT1 demonstrates a valuable role in using both epigenetic agents to optimise the T-cell infiltration effect into the tumour microenvironment by a dramatic increase in its respective chemokines.

Upregulation of cancer-associated antigen expression

We demonstrated the upregulation of human cancer-testis antigens that can be recognised by antigen-presenting cells to affect T-cells for a cytotoxic response. The expression of cancer-associated antigen in PDAC is often inhibited by epigenetic silencing of the promoter region for this antigen and therefore evades detection by the circulating immune system. By reversing this tumour cancer-associated antigen promoter region’s epigenetic silencing, its signalling can be regulated to be available for increased tumour lysis. Treatment of the MiaPaca2 cell line with DZNep and/or 5-AZA for 48 h demonstrated an upregulation of LAGE (relative gene fold 155 ± 41), NY-ESO-1 (relative gene fold 203 ± 10) and SSX-4 (relative gene fold 63 ± 15). Repeat experiments were performed with S2-013 and demonstrated similar upregulation. The WT1 expression was significantly upregulated (relative fold change 15.9 ± 4.6) compared with the untreated control after treatment with DZNep and 5-AZA. The cancer-associated antigen frequency for immune response was increased when combined with the upregulation of cancer-testis antigens as additional targets for T lymphocytes (Figure 2).
Global epigenetic changes with DZNep and 5-AZA treatment

The microassay showed global epigenetic changes in the MiaPaca2 cell line with DZNep and 5-AZA treatment in the cluster heat map compared with control (Supplementary figure 2). When the cluster heat map was focussed on chemokines, (Figure 3a), it demonstrated more genes upregulated in addition to CXCL10, including the family of synovial sarcoma X (SSX) breakpoint proteins, including SSX-4b (26.69 rel. fold), SSX8 (10.25 rel. fold), SSX3 (14.24 rel. fold) and SSX5 (33.02 rel. fold) that are associated with humoral and cellular immune responses in various cancers ($P < 0.01$). CXCL9 (2.3 x 10^2 relative fold change) and CXCL10 (1.0 x 10^5 relative fold change) were upregulated for the combination group of DZNep, 5-Aza and IFN in human pancreatic cancer cell lines S2-013 (CXCL9 relative fold change 2.3 x 102 ± 54.4; CXCL10 relative fold change 1.0 x 105 ± 6782) and MiaPaca2 (CXCL 9 relative fold change 1.2 x 103 ± 411.4; CXCL 10 relative fold change 4.1 x 105 ± 148 961 ($P < 0.01$). AZA, 5-AZA; CB, combination of 5-AZA and DZNepCT, control; DZ, DZNep.

The combination of epigenetic modulation and immunotherapy suppresses tumour growth

In the orthotopic PDAC models with either PAN02 or KPC inoculation, epigenetic therapy combined with immunotherapy was compared for the efficacy for tumour regression. Compared with the untreated group (UT), treatment with 0.2 mg kg$^{-1}$ 5-AZA and 2.5 mg kg$^{-1}$ showed slight tumour regression without statistical significance. However, treatment with 10 mg kg$^{-1}$ anti-PD-L1 monoclonal antibody caused a one-third decrease in tumour weight with statistical

Global epigenetic changes with DZNep and 5-AZA treatment

The microassay showed global epigenetic changes in the MiaPaca2 cell line with DZNep and 5-AZA treatment in the cluster heat map compared with control (Supplementary figure 2). When the cluster heat map was focussed on chemokines, (Figure 3a), it demonstrated more genes upregulated in addition to CXCL10, including the family of synovial sarcoma X (SSX) breakpoint proteins, including SSX-4b (26.69 rel. fold), SSX8 (10.25 rel. fold), SSX3 (14.24 rel. fold) and SSX5 (33.02 rel. fold) that are associated with humoral and cellular immune responses in various cancers ($P < 0.01$). CXCL9 (2.3 x 10^2 relative fold change) and CXCL10 (1.0 x 10^5 relative fold change) were upregulated for the combination group of DZNep, 5-Aza and IFN in human pancreatic cancer cell lines S2-013 (CXCL9 relative fold change 2.3 x 102 ± 54.4; CXCL10 relative fold change 1.0 x 105 ± 6782) and MiaPaca2 (CXCL 9 relative fold change 1.2 x 103 ± 411.4; CXCL 10 relative fold change 4.1 x 105 ± 148 961 ($P < 0.01$). AZA, 5-AZA; CB, combination of 5-AZA and DZNepCT, control; DZ, DZNep.

The combination of epigenetic modulation and immunotherapy suppresses tumour growth

In the orthotopic PDAC models with either PAN02 or KPC inoculation, epigenetic therapy combined with immunotherapy was compared for the efficacy for tumour regression. Compared with the untreated group (UT), treatment with 0.2 mg kg$^{-1}$ 5-AZA and 2.5 mg kg$^{-1}$ showed slight tumour regression without statistical significance. However, treatment with 10 mg kg$^{-1}$ anti-PD-L1 monoclonal antibody caused a one-third decrease in tumour weight with statistical
The combination treatment (0.2 mg kg\(^{-1}\) C0 1 5-AZA, 2.5 mg kg\(^{-1}\) C0 1 DZNep and 10 mg kg\(^{-1}\) C0 1 anti-PD-L1 monoclonal antibody) showed about 50% tumour regression, with statistical significance (\(P < 0.01\)). Consistently, the tumour weight/body weight ratio showed a similar trend with the result of tumour weight (Figure 4a).

In the orthotopic PDAC model of PAN02 inoculation, a further study was performed to investigate whether the treatment of 5-AZA and DZNep could upregulate the antigen presentation machinery. In comparison with UT and anti-PD-L1 treatment, Western blotting analysis showed significant increases in protein levels of transporter associated with antigen processing (TAP)-1 and \(\beta\)-2 microglobulin from both 5-AZA/DZNep treatment and combination treatment (Figure 4b), indicating that the significant tumour regression by epigenetic modulation and immunotherapy was related to the cancer-associated antigen-initiated immune response.

**Increased T-cell lymphocyte infiltration of the tumour microenvironment**

As the upregulation of attracting chemokines and cancer-associated antigen induction (\textit{in vitro}) and upregulation of antigen presentation machinery genes (\textit{in vivo}) has been demonstrated, we anticipated a higher level of T-cell lymphocyte infiltration in the tumour microenvironment in epigenetic therapy combined with immunotherapy. To investigate T-cell trafficking in the tumour microenvironment, we performed immunohistochemistry on the tumour tissues from the orthotopic PDAC models of PAN02 inoculation. Consistent with the tumour regression in the combination therapy group, there was a corresponding highest CD3 and CD8 T-cell infiltration in the combination arm’s tumour microenvironment compared with the untreated control arm (Figure 5a). The clinical significance of increased T-cell migration into the tumour microenvironment is the correlated survival.
improvement seen in patients with resected pancreatic cancer, with the greatest prognosis associated with a higher level of tumour-infiltrating lymphocytes.\textsuperscript{35,36} Similarly, we noted a corresponding level of increased apoptosis associated with the tumour microenvironment. There is the level of highest tumour-infiltrating lymphocytes in the combination arm, as assessed by the TUNEL assay (Figure 5). The increased apoptosis suggests the tumour-infiltrating lymphocyte-associated cell death of pancreatic cancer cells.\textsuperscript{37}

Knockdown model of EZH2 and DNMT1

To validate the effect of EZH2 and DNMT1 inhibition in the drug model of DZNEP and 5-AZA, a cell line of PAN02-KD was established by a double knockdown of EZH2 and DNMT1 to eliminate the possibility of an off-target effect. The knockdown of EZH2 and DNMT1 in PAN02 cells was validated by Western blot (Supplementary figure 3). PAN02-KD-PDAC model was established in C57/BL6 mice inoculated with

Figure 3. (a) Focussed cluster heat map of chemokines demonstrates upregulation in chemoattractants, migratory adhesion proteins and tumour antigen expression with binding peptides for autologous cytotoxic T lymphocytes. (b) Focussed cluster heat map of tumour antigens.
5.0 × 10^5 PAN02-KD cells. The PAN02-KD-PDAC mice were treated with intraperitoneal injections of murine anti-PD-L1 antibodies three times a week for 3 weeks, while the untreated PAN02-PDAC mice and the PAN02-PDAC mice with combination therapy were used as controls. Compared with the PAN02-PDAC without treatment, double knockdown of EZH2 and DNMT1 in PAN02 cells demonstrated a modest reduction in tumour growth in the PAN02-KD-PDAC mice. However, the anti-PD-L1 treatment to the PAN02-KD-PDAC mice demonstrated a statistically significant reduction in tumour growth. Although statistical significance was not reached, their tumour weight was lower than that of the PAN02-PDAC mice with combination therapy (Figure 6). The growth inhibition in the PAN02-PDAC mice with anti-PD-L1 treatment recapitulated the findings of increased chemokine expression, upregulation of cancer-associated antigen and antigen presentation machinery, and apoptosis observed in the combination arm using the epigenetic therapy with DZNep, 5-AZA, and anti-PD-L1.

**Increased infiltration of CD4⁺IL-17⁺ cells in the tumour tissues**

The lineages of CD4⁺ T-cell subsets include pro-inflammatory T helper (Th) cells and anti-inflammatory regulatory T-cells (Treg). In contrast, naive CD4⁺ T-cells differentiation is under respective Th1, Th2, Th17 and Treg polarising conditions. To understand the impact on the potential T-cell lineage after epigenetic stimulation of immune response from anti-PD-L1 on the surrounding tumour immune microenvironment, we performed an immune fluorescent analysis to detect induction of IL-17-producing helper cells (Th17) from naive CD4 precursor cells. There was a significant increase in the number of CD4⁺IL-17⁺ cells in the tumour tissues from PAN02-PDAC mice.
with combination therapy. Knockdown of EZH2 and DNMT1 also contributed to the increase in number of CD4+IL-17+ cells in the tumour tissues, while the number of CD4+IL-17+ cells significantly increased when PAN02-KD-PDAC mice were treated with anti-PD-L1 therapy (Figure 7).

**DISCUSSION**

There are multiple barriers to immunotherapy for PDAC, including lack of cancer-associated antigen expression, lack of effector T-cell trafficking and an immune-suppressive tumour microenvironment. The role of immunotherapy in pancreatic cancer has been limited thus far and requires additional novel combination strategies to augment the treatment response potentially. In the current study, we strategised to address several known obstacles for immunotherapy in pancreatic cancer modifiable by epigenetic modulation alone, acknowledging that there may be additional barriers yet to be elucidated. Our results show that specific aberrant epigenetic expression, which has been responsible for repressing cancer-associated
antigen expression on the cell surface and suppressing T-cell trafficking into the tumour microenvironment, can be reversed by downregulation of chemokine genes. Epigenetic therapy with DZNep and 5-AZA can augment the effect of anti-PD-L1 immunotherapy via upregulation of the previously repressed cancer-associated antigen expression as immune targets towards cytotoxic T-lymphocyte lineage and increase T-cell infiltration into the tumour microenvironment to allow cancer-associated antigen interaction to occur. A high frequency of cancer-associated antigen expression on the PDAC cell surface is critical for the immune response for effective tumour regression; however, there is currently a limited immune response because of the low somatic mutations that provide foreign-tumour-associated antigens in PDAC.\textsuperscript{17,40}

Increased tumour-infiltrating lymphocyte migration into the tumour microenvironment to allow cancer-associated antigen interaction to occur. A high frequency of cancer-associated antigen expression on the PDAC cell surface is critical for the immune response for effective tumour regression; however, there is currently a limited immune response because of the low somatic mutations that provide foreign-tumour-associated antigens in PDAC.\textsuperscript{17,40}

Figure 6. Orthotropic PDAC models in C56BL6 mice injected with PAN02-KD cells generated by short hairpin lentiviral knockdown of EZH2 (shEZH2) and DNMT1 (shDNMT1). (a) Gross anatomy in four groups of orthotropic models on C56BL6 mice with inoculation of PAN02-KD cells (untreated and anti-PD-L1 treatment) and with inoculation of PAN02-KD cells (untreated and combination treatment). (b) Tumour weights and ratio of tumour weight/body weight in four groups of orthotropic models on C56BL6 mice with inoculation of PAN02-KD cells (untreated and anti-PD-L1 treatment) and with inoculation of PAN02-KD cells (untreated and combination treatment). ***P < 0.001. Animal number = 5 in each group. This is an unreplicated experiment.
correlates with improved survival. In this in vivo study, we demonstrate the increased migration of T lymphocytes into the tumour microenvironment by increasing previously epigenetically silenced chemokine expression, CXCL9 and CXCL10, by epigenetic modulation utilising EZH2 and DNMT1 inhibitors in PDAC. In addition to the canonical JAK-STAT1 pathway of modulating key immune effectors, IFN-γ also serves a role in chromatin remodelling to activate poised chromatin-containing enhancers of immune effector genes. The combination of IFN-γ with DZNep facilitated the demethylation of the H3K27me3 on promoters of CXCL9 and CXCL10 that has been previously demonstrated. While IFN-γ alone can decrease H3K27me3 methylation partially, the combination of DZNep provided a synergistic upregulation of CXCL9/10. To further validate the epigenetic drug treatment model’s specificity, we performed specific gene knockdown of the epigenetic targets EZH2 (shEZH2) and DNMT1 (shDNMT1) and demonstrated potentiation of tumour regression by anti-PD-L1 after shEZH2 and shDNMT1. Thus, we demonstrated that the epigenetic modulation combined with the checkpoint inhibitor enhances immune response as a result of an increase in T-cell infiltration. This combination therapy can overcome the immunosuppressive microenvironment, thereby causing enhanced tumour regression in comparison with either immunotherapy or epigenetic therapy alone. Our finding has significant clinical relevance, as the combination of increased cancer-associated antigen frequency and T-cell infiltration in PDAC has been associated with prolonged survival among patients.

The potential use of epigenetic modulation of immunotherapy for pancreatic cancer patients does not exclude chemotherapy and radiation. Instead, it presents a potential multimodality combination: neoadjuvant chemoradiation using immunotherapy for patients with locally advanced pancreatic cancer, recurrent disease and/or metastatic setting. With a greater understanding of molecular subtypes of pancreatic cancer emerging, greater therapeutic specificity in selecting various

Figure 7. Dual immunofluorescent staining using anti-CD4 and anti-IL-17A to detect the induction of IL-17-producing helper cells (Th17) from naive CD4 precursor cells in four groups of orthotopic models on C56/BL6 mice with inoculation of PAN02-KD cells (untreated and anti-PD-L1 treatment) and with inoculation of PAN02-KD cells (untreated and combination treatment). HPF: High power field. Scale bar = 100 μm. CB: combination of 5-AZA/DZNep and anti-PD-L1. *P < 0.05; **P < 0.01. All experiments were repeated three times.
agents with the underlying epigenetic driver of individual subtypes may be warranted. The recent Compass Trial was able to stratify patients by classical versus more chemotherapy-resistant basal-like subtype by the magnitude of GATA6 expression. Epigenetic therapy has the potential to restore the biomarkers of poor therapeutic responses of basal-like subtypes and subsequently improve response and survival. Furthermore, there are potential benefits from the immunogenic impact of chemotherapy and radiation in creating damage-associated molecular patterns from its treatment (cancer-associated antigens) that can further potentiate the effect of immunotherapy by increasing MHC complex and lower Treg/TIL ratio.

In addition to T-cell infiltration in the tumour microenvironment, T-cell lineage is impacted by the change in signalling from naïve CD4 to Th17 cell induction by stimulation of RORγ-T signalling. Th17 helps facilitate cytokine release and facilitates a pro-inflammatory cascade that is potentially beneficial for converting immune silent tumour microenvironment to immunotherapy.

There are several limitations to our study. First, the PDAC model was established in mice with a standard murine immune system rather than a transgenic model with a humanised T-cell repertoire that could have closer human model implications. Second, we acknowledge there are additional neoantigen targets that have not been elucidated in this study that could be further evaluated for possible target in the future. However, despite these limitations, we demonstrated that immunotherapy can be augmented by epigenetic modulation for a known immunosilent tumour. Our experiments utilised four different pancreatic cell lines for both in vitro and in vivo studies with similar reproducible results. In addition to using the immunocompetent models with inoculation of PAN02 cells and KPC cells to test the epigenetic and immunotherapy drugs, we further performed appropriate knockdown models of EZH2 and DNMT1 in PAN02 model to confirm their role in immunomodulation for PDAC by activating expression of previously repressed immune activating gene targets.

In conclusion, we demonstrated that immunotherapy for PDAC can be potentiated with epigenetic therapy by increasing cancer-associated antigen expression and increased T-cell trafficking across the immunosuppressive tumour microenvironment via upregulation of the repressed chemokines and increased apoptosis with subsequent tumour regression. Clinical trials of multimodality treatment for patients with locally advanced, recurrent and/or metastatic pancreatic cancer may be warranted.

**METHODS**

**Cell lines and drug treatments**

Human pancreatic adenocarcinoma cell lines S2-013, MiaPaca-2 and murine PAN02 were obtained from the National Cancer Institute-Division of Cancer Treatment and Diagnosis (NCI-DCTD) Tumour Repository. KPC (Pdx1-Cre, LSL-KrasG12D/+ ) cell line was obtained from Ximbio (Item No. 153474). The Cell culture supplies included in RPMI-1640 medium (ATCC 30-2001), Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning Cellgro), Fetal Bovine Serum (FBS) (Sigma-Aldrich, MO, USA) and Penicillin/Streptomycin (Pen/Strep) (Corning Cellgro). NCI-DCTD provided validation of the cell lines upon purchase. 5-azacytidine (5-AZA) was obtained from Cayman Chemicals (Item No. 11164), 3-Deazaneplanocin A (DZNep) from Sigma-Aldrich (Item No. SML0305), INF-gamma from Millipore (Item No. IF002) and murine anti-PD-L1 were obtained from BioXcell (Item No. BE0101). Anti-TAP-1 antibody was obtained from Proteintech (11114-1-AP). Anti-microglobulin antibody (ab218230), anti-IL-17 antibody (ab79056), anti-CD3 antibody [SP7] (ab16669), anti-CD8 antibody (SP7) (ab16669), anti-CD8 α antibody [EPR21769] (ab217344) and Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 594) (ab150064) were purchased from Abcam. Anti-HLA-A antibody (303358) was purchased from US Biological life science. Anti-CD4 (FITC Conjugate) (96127) was purchased from Cell Signaling Technology.

**Cell culture and treatments**

S2013, MiaPaca-2 and KPC cells were cultured in DMEM with 10% FBS and Pen/Strep in a 5% CO2 incubator at 37°C. PAN02 cells were maintained in RPMI 1640 supplemented with 10% FBS and 2 mmol L⁻¹ L-Glutamine. For the in vitro study, S2013 and MiaPaca-2 cells were seeded in a 6-well plate at a density of 1 × 10⁵ cells. When 80% confluence was reached, the cells were washed with PBS and treated with the culture media with or without 5 μmol of 5-AZA and/or 5 μmol DZNep with/without 10 ng mL⁻¹ IFN-γ. The doses of 5-AZA and DZNep have been previously utilised in the literature, effectively inhibiting DNMT1 and EZH2, respectively. The cells were treated for 48 h, washed with PBS and harvested for RT-PCR analysis. All the in vitro experiments were repeated at least three times.

**Generation of stable cells expressing shRNA constructs**

We used a commercially available fourth-generation lentivirus packing system (Lenti-X, Takara-Clontech; Item No. 631278) for generating stable cell lines. Briefly, blasticidin-resistant shDNMT1 (Vectorbuilder, CA, USA) and puromycin-resistant shEZH2 (Sigma-Aldrich) vectors were
obtained, amplified and purified for packing. For generating lentivirus, Lenti-X reagent was mixed with 6 µg of shRNA plasmid and transfected in a 293 T-cell line for packing. Harvested lentivirus was used to transduce PAN02 cells to knockdown (KD) both EZH2 and DNMT1 using polybrene with established protocol. PAN02-KD cell line was established by transducing with shRNA targeting EZH2 (shEZH2), DNMT1 (shDNMT1) or both sham sequences (shControl; Sigma-Aldrich) according to the manufacturer instructions. Cell lines were selected with puromycin (Sigma-Aldrich) and expanded after confirmation of knockdown by qRT-PCR and immunoblot.

In vivo experiments

Eight-week-old male C57/BL6 mice (Jackson Laboratories, Bar Harbor, ME, USA) were housed four per cage, given rodent chow and tap water and maintained at 22°C and on a 12-h light/dark cycle. To establish orthotopic PDAC models, a 1.5-cm midline laparotomy incision was made under anaesthesia. PAN02/KPC/PAN02-KD cells were injected at a concentration of 1 x 10⁶ cells/injection into the pancreas. The abdominal wall was closed in two layers using a 5-0 Vicryl suture (Ethicon, Incorporated, New Brunswick, NJ, USA). For the PAN02/KPC inoculation (Table 1), the mice were randomly assigned into four treatment groups: (1) saline; (2) drugs alone (0.2 mg kg⁻¹ 5-AZA, 2.5 mg kg⁻¹ DZNep); (3) anti-PD-L1 alone (10 mg kg⁻¹ anti-PD-L1 monoclonal antibody) and (4) combination (0.2 mg kg⁻¹ 5-AZA, 2.5 mg kg⁻¹ DZNep, 10 mg kg⁻¹ anti-PD-L1 monoclonal antibody). An equal amount of 250 µL solution for treatment via intraperitoneal injection was performed every Monday, Wednesday and Friday for 3 weeks. For the PAN02-KD inoculation (Table 1), the mice were randomly assigned to receive either saline or anti-PD-L1 alone (10 mg kg⁻¹ anti-PD-L1 monoclonal antibody) via 250 µL solution i.p. every Monday, Wednesday and Friday for 3 weeks, while the PAN02 inoculated mice with the treatment of saline and anti-PD-L1 were used as controls. For all mice with tumour inoculation, tumour growth was monitored weekly by ultrasound with a small linear probe array. After a 3-week treatment, the mice were monitored weekly by ultrasound with a small linear probe and terminated when they reached an endpoint of maximal tumour size.

Microarray

In vivo experiments

Tumour samples were obtained for MiaPaca cells treated with a combination 5-AZA and DZNep in vitro according to the cell culture assay methods described above. The treatment group, as well as the controls, was tested in triplicate. The samples were stored at −80°C until used in treatments. Total RNA from each sample was quantified using NanoDrop ND-100. Clarion S assay was used to perform a microarray analysis of global genetic changes by comparing the four experimental groups.

Western blot

The protein levels for the biomarkers were semiquantified by Western blot analysis as described previously. Electrophoresis was performed on 12% SDS-PAGE gel, and the proteins were transformed into nitrocellulose membrane. The membranes were incubated with the primary antibodies (Anti-TAP-1 antibody; anti-iL-2 microglobulin antibody; and anti-HLA-A antibody) overnight at 4°C and with secondary antibody for 1 h at room temperature. The antigen–antibody complexes were then visualised using an ECL kit (Amersham, Piscataway, NJ, USA). The protein bands were quantified by densitometry analysis.

Immunohistochemistry and immunofluorescent staining

Immunohistochemistry (IHC) staining was performed on 20-µm, paraffin-embedded sections of the specimen using DAKO EnVision+ System Kit (DAKO EnVision+ System, HRP, Carpinteria, CA, USA) as previously reported. In brief, sections were de-paraffinised and hydrated, and antibodies of CD-3 and CD88 were applied and incubated with labelled polymer for 30 min at room temperature. The substrate-chromogen solution (diaminobenzidine) was added as a visualisation reagent; 0.25% bovine serum albumin in phosphate-buffered saline without antibody was used as a negative control. Immunofluorescent staining was performed

Table 1. Treatment in three models by grouping

| Model                  | Group            | Number |
|------------------------|------------------|--------|
| PAN02 cell inoculation | Saline (untreated) | 10     |
|                        | DZNep+5-AZA      | 5      |
|                        | anti-PD-L1       | 5      |
|                        | DZNep+5-AZA + anti-PD-L1 | 10     |
| KPC cell inoculation   | Saline (untreated) | 6      |
|                        | DZNep+5-AZA      | 6      |
|                        | anti-PD-L1       | 6      |
|                        | DZNep+5-AZA + anti-PD-L1 | 6     |
| PAN02-KD cell inoculation | Saline (untreated) | 5      |
|                        | DZNep+5-AZA + anti-PD-L1 | 5     |
for the tumour tissues of the orthotopic PDAC mouse models. In brief, the OCT-embedded frozen tissue sections were used for immunofluorescent analysis. The slides of tissues were fixed in 1:1 acetic acid/methanol for 10 min. After washing with PBS, then incubated with the antibodies of CD4 (RM4-5, mAb, FITC Conjugate, #96127, Cell Signaling; 1:100 dilution) and IL-17A (ab79056, Abcam) (1:100 dilution) at room temperature for 2 h. After washing with PBS, the tissues were incubated with donkey Anti-Rabbit IgG H&L (Alexa Fluor® 594, ab150064, Abcam) (1:200 dilution) at room temperature for 2 h. DAPI staining was performed as counterstaining, and images were captured using an Olympus IX51-DP72 image system (Olympus, Pittsburgh, PA, USA). Digital images were acquired with the Olympus 1×51 microscope (Olympus) at 20× magnification using an Olympus DPT2 digital camera. Computer image analysis of staining intensity was performed via the cellSense Dimension imaging system (Olympus Life Science, Tokyo, Japan).

**Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay**

TUNEL staining was performed using an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon, Billerica, CA, USA). After de-paraffin and hydration, the sections were treated with proteinase K (20 mg L⁻¹) for 15 min and then incubated with terminal deoxynucleotidyl transferase (TdT) and digoxigenin-11-dUTP for 1 h at 37°C. Anti-digoxigenin antibody conjugated with horseradish peroxidase (HRP) along with the substrate (DAB-H₂O₂) was used for visualisation. Apoptotic cell death was quantitatively analysed by counting the TUNEL-positive cells in 10 fields for each section at 20× magnification. The apoptotic index was presented as TUNEL-positive cells per 100 cells.

**Statistical analysis**

SEM is indicated by bars on all figures and was calculated using Microsoft Office Excel 2018. All experiments were done with a minimum of triplicate samples, and P-values were calculated with 2-tailed t-tests unless otherwise indicated.

**FUNDING**

No outside funding was received for these studies or the resulting article.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

Young Hong, Yan Li and Robert Martin conceived and designed the study. Material preparation, data collection and analysis were performed by Young Hong. Harshul Pandit worked on the gene knockdown of EZH2 and DNMT1 in PAN02 cells. Young Hong and Zachary Pulliam worked on cell culture and treatment. Xingtong Wang, Youxi Yu, Yujia Chen, Min Tan and Qianqian Zheng worked on the animal model. IHC and Western blot. Andrew Lin, Jeremy Badach and Ping Zhang worked on microarray and data analysis. The first draft of the manuscript was written by Young Hong, Yan Li and Neal Bhutiani, and all authors commented on versions of the manuscript. All authors read and approved the final manuscript.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

**REFERENCES**

1. Ferlay J, Colombet M, Soerjomataram I et al. Cancer statistics for the year 2020: an overview. *Int J Cancer* 2021; 149: 778–789.

2. MacCurtain BM, Quirke NP, Thorpe SD, Gallagher TK. Pancreatic ductal adenocarcinoma: relating biomechanics and prognosis. *J Clin Med* 2021; 10: 2711.

3. Brown ZJ, Cloyd JM. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. *J Surg Oncol* 2021; 123: 1432–1440.

4. Chapman BC, Gleisner A, Rigg D et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine Abraxane in patients with pancreatic adenocarcinoma. *JOP* 2018; 19: 75–85.

5. Voelker R. Reducing lung cancer progression with immunotherapy. *JAMA* 2018; 319: 1314.

6. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2017; 377: 1345–1356.

7. Long GV, Weber JS, Larkin J et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. *JAMA Oncol* 2017; 3: 1511–1519.

8. Sahin IH, Askan G, Hu ZI, O’Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? *Ann Oncol* 2017; 28: 2950–2961.

9. Du W, Pasca di Magliano M, Zhang Y. Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer. *Front Oncol* 2021; 11: 682217.

10. Chen Y, Kim J, Yang S et al. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. *Cancer Cell* 2021; 39: 548–565 e546.

11. Diana A, Wang LM, D’Costa Z et al. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. *Oncotarget* 2016; 7: 72819–72832.

12. Samulitis BK, Pond KW, Pond E et al. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. *Cancer Biol Ther* 2015; 16: 43–51.

13. Jiao F, Hu H, Yuan C et al. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. *Int J Oncol* 2014; 45: 1523–1530.
14. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19: 698–711.

15. Moffitt RA, Marayati R, Flate EL et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015; 47: 1168–1178.

16. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818–1822.

17. Bailey P, Chang DK, Forget MA et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep 2016; 6: 35848.

18. Eyres M, Lanfredini S, Xu H et al. TET2 drives Shmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes. Gastroenterology 2021; 161: 653–668 e616.

19. Han T, Zhuo M, Hu H, Jiao F, Wang LW. Synergistic effects of the combination of 5-AzaCdR and suberylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Oncol Rep 2018; 39: 264–270.

20. Susanto JM, Colvin EK, Pinese M et al. The epigenetic agents suberylanilide hydroxamic acid and 5AZA2′ deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. Int J Oncol 2015; 46: 2223–2230.

21. Wierda RJ, van den Elsen PJ. Genetic and epigenetic regulation of CCR5 transcription. Biology (Basel) 2012; 1: 869–879.

22. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine gene silencing in decidual stromal cells regulates CCR5 transcription. Lab Invest 2019; 99: 85–92.

23. Wang Y, Shi T, Song X, Liu B, Wei J. Gene fusion neoantigens: emerging targets for cancer immunotherapy. Cancer Lett 2021; 506: 45–54.

24. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69–74.

25. Mar VJ, Wong SQ, Li J et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 2013; 19: 4589–4598.

26. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251–263.

27. Yang D, Han X, Li D et al. Molecular diagnosis and clinical outcome of a lung cancer patient with TP53-E2B5K mutated Li-Fraumeni syndrome harboring a somatic EGFR-KDD mutation. Am J Transl Res 2020; 12: 6689–6693.

28. Blackford A, Parmigiani G, Kessler TW et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009; 69: 3681–3688.

29. Lawrence MS, Stojanov P, Polak P et al. Mutation heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214–218.

30. Park TS, Groh EM, Patel K, Kerkar SP, Lee CC, Rosenberg SA. Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers. J Immunother 2016; 39: 1–7.

31. Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol 2018; 9: 1044.

32. Yasmin R, Siraj S, Hassan A, Khan AR, Abbasi R, Ahmad N. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies. Mediators Inflamm 2015; 2015: 210703.

33. Tahkola K, Mecklin JP, Wirta EV et al. High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch 2018; 472: 653–665.

34. Yang D, Han X, Li D et al. Molecular diagnosis and epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015; 527: 249–253.

35. Aires DJ, Yoshida M, Richardson SK et al. T-cell trafficking plays an essential role in tumor immunity. Lab Invest 2019; 99: 85–92.

36. Wang Y, Shi T, Song X, Liu B, Wei J. Gene fusion neoantigens: emerging targets for cancer immunotherapy. Cancer Lett 2021; 506: 45–54.

37. Mar VJ, Wong SQ, Li J et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 2013; 19: 4589–4598.

38. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251–263.

39. Yang D, Han X, Li D et al. Molecular diagnosis and clinical outcome of a lung cancer patient with TP53-E2B5K mutated Li-Fraumeni syndrome harboring a somatic EGFR-KDD mutation. Am J Transl Res 2020; 12: 6689–6693.

40. Blackford A, Parmigiani G, Kessler TW et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009; 69: 3681–3688.

41. Lawrence MS, Stojanov P, Polak P et al. Mutation heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214–218.
47. Kemp CD, Rao M, Xi S et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. *Clin Cancer Res* 2012; 18: 77–90.

48. Pandit H, Tinney JP, Li Y et al. Utilizing contrast-enhanced ultrasound imaging for evaluating fatty liver disease progression in pre-clinical mouse models. *Ultrasound Med Biol* 2019; 45: 549–557.

49. Cui G, Martin RC, Liu X et al. Serological biomarkers associate ultrasound characteristics of steatohepatitis in mice with liver cancer. *Nutr Metab (Lond)* 2018; 15: 71.

50. Zheng Q, Martin RC, Shi X et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. *Theranostics* 2020; 10: 9923–9936.

---

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.